News Search Results
Apr 28, 2026, 07:30 ET Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma
procurement contracts with the U.S. Government or other countries, that it will be able to compete with larger and better financed competitors in the biotechnology industry, that changes in health care practice, third party reimbursement limitations and Federal and/or state health care reform initiatives will
More news about: SOLIGENIX, INC.
Apr 28, 2026, 07:00 ET Ascidian to Highlight Progress of Lead Program in Stargardt and Platform Advancements Across Therapeutic Areas at ASGCT 2026 Annual Meeting
Ascidian Therapeutics, a biotechnology company seeking to treat human diseases by rewriting RNA, today announced it will present two oral presentations and one poster presentation at
More news about: Ascidian Therapeutics
Apr 28, 2026, 07:00 ET Honeywell Announces Board of Directors for Honeywell Aerospace
including as Chief Executive Officer of William Blair Investment Management. She currently serves on the boards of MetLife, MSCI, Inc. and Sana Biotechnology, Inc.About HoneywellHoneywell is an integrated operating company serving a broad range of industries and geographies
More news about: Honeywell
Apr 28, 2026, 06:30 ET Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced the appointment of Michael A. Panzara, M.D.,
More news about: Immunic, Inc.
Apr 28, 2026, 06:17 ET MEDP Investor Alert: Medpace Sued for Securities Fraud Amid Cancellation Rates
Fraud?Medpace is a clinical contract research organization focused on providing scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries. During the relevant period, Medpace allegedly misled investors concerning its
More news about: Bleichmar Fonti & Auld LLP
Apr 28, 2026, 06:00 ET HERVolution Therapeutics Appoints Dr. László B. Tankó to Scientific Advisory Board to Strengthen Cardiometabolic Clinical Development Strategy
COPENHAGEN, Denmark and NEW YORK, April 28, 2026 /PRNewswire/ -- HERVolution Therapeutics, a biotechnology company pioneering human endogenous retrovirus (HERV)-targeting immunotherapies for oncology, metabolic diseases, and longevity, today announced
More news about: HERVolution Therapeutics
Apr 27, 2026, 20:33 ET IBRX SHAREHOLDER UPDATE: ImmunityBio (IBRX) Sued After FDA Flags Misleading Cancer Claims, Shares Plunge 21%, $2B Market Cap Lost -- Hagens Berman
[email protected] 844-916-0895ImmunityBio, Inc. (IBRX) Securities Class Action: ImmunityBio is a biotechnology company focused on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system
More news about: Hagens Berman Sobol Shapiro LLP
Apr 27, 2026, 17:00 ET WesternU COMP-Northwest welcomes local kindergarteners to annual Mini-Medical School
Oregon and Pomona, Calif., is an independent nonprofit health professions university, conferring degrees in osteopathic medicine, physical therapy, biotechnology and pharmaceutical sciences, dental medicine, medical sciences, nursing, optometry, pharmacy, physician assistant studies, podiatric medicine, and
More news about: Western University of Health Sciences (WesternU)
Apr 27, 2026, 16:30 ET Apertura Gene Therapy and Scientists from the Broad Institute to Share Data on TfR1 CapX™, a Novel Capsid Targeting the Central Nervous System (CNS), at the American Society of Gene and Cell Therapy (ASGCT) Annual Meeting
—NEW YORK, April 27, 2026 /PRNewswire/ -- Apertura Gene Therapy, a biotechnology company developing next-generation AAV capsids for delivering genetic medicines, along with scientists from the Broad Institute of MIT and Harvard,
More news about: Apertura Gene Therapy
Apr 27, 2026, 16:25 ET BioLab Holdings Announces Strategic Partnership with SweetBio® to Expand Continuum of Wound Care Solutions
innovation, strategic partnerships, and commercialization, today announced a strategic distribution partnership with SweetBio®, Inc., a biotechnology company focused on bioengineered wound products that leverage collagen and medical-grade Mānuka honey to support care of acute and chronic wounds.
More news about: BioLab Sciences
Apr 27, 2026, 10:15 ET QuantiPath Appoints Industry Veteran Roger Schaller to Board of Directors
leadership driving its mission to bring faster, more accurate testing to the food safety industry.About QuantiPathQuantiPath is a biotechnology company revolutionizing food safety testing through precision genetic diagnostics. Its flagship product, GenoPATHX™, is the only rapid test kit
More news about: QuantiPath
Apr 27, 2026, 08:45 ET Decoy Therapeutics to Present at Two Peptide Therapeutics Conferences in Boston
CAMBRIDGE, Mass., April 27, 2026 /PRNewswire/ -- Decoy Therapeutics Inc. (Nasdaq: DCOY), a preclinical-stage biotechnology company pioneering Designable Multi-Antivirals (D-MAVs ™), a new category of antivirals engineered to target shared viral mechanisms
More news about: Decoy Therapeutics, Inc
Apr 27, 2026, 08:44 ET BioMarin Completes Acquisition of Amicus Therapeutics
PRESCRIBING INFORMATION for OPFOLDA (miglustat).About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Apr 27, 2026, 08:00 ET Avista Therapeutics Announces Presentations at Upcoming Medical Meetings
avistatx.com) is a biotechnology company spun out of the University of Pittsburgh, and built on deep clinical, computational and gene therapy expertise, whose mission is to break
More news about: Avista Therapeutics
Apr 27, 2026, 08:00 ET Stealth BioTherapeutics to Present Clinical Data for Bevemipretide Eye Drops at the Association for Research in Vision and Ophthalmology 2026 Annual Meeting
Mass., April 27, 2026 /PRNewswire/ -- Stealth BioTherapeutics (the "Company" or "Stealth"), a commercial-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today
More news about: Stealth BioTherapeutics Inc.
Apr 27, 2026, 07:30 ET BioMarin to Host First Quarter 2026 Financial Results Conference Call and Webcast on Monday, May 4, 2026, at 4:30pm ET
call will be archived on the site for one week following the call.About BioMarinBioMarin is a leading, global rare disease biotechnology company focused on delivering medicines for people living with genetically defined conditions. Founded in 1997, the San Rafael, California-based
More news about: BioMarin Pharmaceutical Inc.
Apr 27, 2026, 07:00 ET Armata Pharmaceuticals Announces Appointment of Biopharmaceutical Commercial Executive Daniel B. Gilmer, Ph.D. to its Board of Directors
April 27, 2026 /PRNewswire/ -- Armata Pharmaceuticals, Inc. (NYSE American: ARMP) ("Armata" or the "Company"), a late clinical-stage biotechnology company focused on the development of high-purity, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat
More news about: Armata Pharmaceuticals, Inc.
Apr 27, 2026, 06:47 ET Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration
More news about: Cellenkos, Inc.
Apr 27, 2026, 06:45 ET Lilly to acquire Ajax Therapeutics to advance outcomes for patients with myelofibrosis and polycythemia vera
life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges:
More news about: Eli Lilly and Company
Apr 27, 2026, 06:21 ET Cellenkos, Inc. Announces FDA Clearance to Initiate Phase 2 Clinical Trial of CK0801 (Allogeneic Cord Blood-Derived Tregs) for Aplastic Anemia
HOUSTON, April 27, 2026 /PRNewswire/ -- Cellenkos®, Inc., a clinical-stage biotechnology company, developing allogeneic, tissue-targeted regulatory T cell (Treg) therapies, today announced the receipt of U.S. Food and Drug Administration
More news about: Cellenkos, Inc.
Apr 27, 2026, 03:14 ET RIMAN verbindet APAC-Märkte in Macau durch Strategie, Innovation und neue Produkteinführungen
auch seine Forschungspipeline hervor. Dr. Hee-sik Kim, Technischer Leiter von ASK LABS und Forscher am Korea Research Institute of Bioscience and Biotechnology, stellte ein pflanzenbasiertes Biomaterial vor, das aus einem firmeneigenen Chlorella-Stamm aus Jeju gewonnen wird. Dieses Material befindet sich
More news about: RIMAN
Apr 26, 2026, 20:10 ET Ascletis Completes Enrollment in U.S. Phase II Study of ASC30, an Oral Small Molecule GLP-1R Agonist, for the Treatment of Diabetes
weekly from 1 mg to target doses of 40 mg, 60 mg and 80 mg.About Ascletis Pharma Inc.Ascletis Pharma Inc. is a fully integrated biotechnology company focused on the development and commercialization of potential best-in-class and first-in-class therapeutics to treat metabolic diseases.
More news about: Ascletis Pharma Inc.
Apr 26, 2026, 07:00 ET Brii Bio Presents Cross-Study Analysis of Post-Treatment HBsAg Rebound at APASL 2026
the Greater China territory from Vir Biotechnology, Inc. in 2020. In May 2024, the CDE of China's NMPA granted elebsiran Breakthrough Therapy Designation.About Brii BioBrii Biosciences Limited ("Brii Bio", stock code: 2137.HK) is a biotechnology company developing therapies to improve
More news about: Brii Biosciences Limited
Apr 26, 2026, 07:00 ET 騰盛博藥在APASL 2026發表治療結束後HBsAg反彈的跨研究分析結果
iRNA）研究性藥物，旨在降解HBV RNA轉錄本及限制乙型肝炎表面抗原的產生，其具有針對HBV及丁型肝炎病毒（HDV）的直接抗病毒活性。其是首個進入臨床的採用增強穩定化學增強技術的siRNA，以增強穩定性並最大程度地減少脫靶活性，從而有可能提高治療指數。騰盛博藥於2020年從Vir Biotechnology, Inc. 獲得了在大中華地區開發和商業化elebsiran的獨家權益。2024年5月，中國國家藥品監督管理局（NMPA）藥品審評中心（CDE）授予elebsiran突破性療法認定。關於騰盛博藥騰盛博藥（股票代碼：2137.HK）是一家生物技術
More news about: 騰盛博藥生物科技有限公司
Apr 24, 2026, 16:01 ET AMGEN ANNOUNCES WEBCAST OF 2026 FIRST QUARTER FINANCIAL RESULTS
best of biology and technology, Amgen reaches millions of patients with its medicines.More than 45 years ago, Amgen helped establish the biotechnology industry at its U.S. headquarters in Thousand Oaks, California, and it remains at the cutting edge of innovation, using technology and human genetic
More news about: Amgen